Le Lézard
Classified in: Health, Science and technology, Business
Subject: TRI

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

KRAKOW, Poland, June 14, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, presents clinical and preclinical data from RVU120 at the 2024 European Hematology Association Congress (EHA), June 13-16, Madrid, Spain.

"We are thrilled to share the advancements in RVU120 research and its clinical development, emphasizing its significant potential in addressing unmet needs in hematologic malignancies.", states Dr. Hendrik Nogai, Chief Medical Officer, Ryvu Therapeutics. "We are proud of the successful initiation of our Phase II studies. It is reassuring that the initial clinical safety data of RVU120 in combination with venetoclax, allow us to continue testing the compelling preclinical evidence of synergism in patients. Beyond AML and HR-MDS, we continue to work hard on new therapeutic strategies for patients with myeloproliferative neoplasms. Over the upcoming months, we are expecting a ramp up of patient enrollment and data readouts, and we remain committed to developing innovative treatments that can provide improved outcomes for patients in need." ? underlines Dr. Hendrik Nogai, Chief Medical Officer, Ryvu Therapeutics.

Poster highlights:

Poster Title: RVU120, a first-in-class CDK8 inhibitor for the treatment of relapsed/refractory AML and high-risk MDS: preliminary results from two ongoing studies.
Poster Number: P600

Session date and time: Friday, June 14 (9:00 CET on the online platform, 18:00 CET for the poster presentation)

The poster includes data on 30 evaluable patients out of 38 total dosed patients in the Phase I trial (RIVER-51) and initial data from the Phase II trial (RIVER-52).

Poster Title: Synergistic potential of RVU120, a first-in-class CDK8/CDK19 inhibitor, with venetoclax in AML: preclinical and initial clinical insights.
Poster Number: P525

Session date and time:  Friday, June 14 (9:00 CET on the online platform, 18:00 CET for the poster presentation)

Poster Title: CDK8/19 Inhibition: A Promising Therapeutic Strategy in Myeloproliferative Neoplasms.
Poster Number:  P1018

Session date and time:   Friday, June 14 (9:00 CET on the online platform, 18:00 CET for the poster presentation)

Investor Event:

Ryvu will host a webinar on Friday, June 14, at 9:30 CET, covering the latest data and potential of RVU120. To join the webcast, please register here: https://ryvu.clickmeeting.com/ryvu-eha-2024-results

About Ryvu Therapeutics 

Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small-molecule therapies that address emerging targets in oncology. Internally discovered pipeline candidates use diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, and immuno-oncology targets.

Ryvu's most advanced programs include RVU120, a selective CDK8/CDK19 kinase inhibitor with the potential to treat hematological malignancies and solid tumors, currently in Phase II development (i) as a monotherapy for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and high-risk myelodysplastic syndromes (HR-MDS) as well as (ii) in combination with venetoclax for the treatment of patients with r/r AML. Another clinical program, SEL24 (MEN1703), is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group. Ryvu Therapeutics has signed multiple partnering and licensing deals with global companies, including BioNTech and Exelixis.

The Company was founded in 2007 and is headquartered in Kraków, Poland. Ryvu is listed on the Warsaw Stock Exchange and is a component of the mWIG40 index. For more information, please see www.ryvu.com

SOURCE Ryvu Therapeutics

These press releases may also interest you

at 06:00
Vertiv Holdings Co , a global provider of critical digital infrastructure and continuity solutions, today reported financial results for its second quarter ended June 30, 2024. Vertiv reported second quarter 2024 net sales of $1,953 million, an...

at 06:00
Pacific Premier Bancorp, Inc. (the "Company" or "Pacific Premier"), the holding company of Pacific Premier Bank (the "Bank"), reported net income of $41.9 million, or $0.43 per diluted share, for the second quarter of 2024, compared with net income...

at 05:55
Mid-Year Highlights Unprecedented population pressures from immigration and migratory exchanges across regions and provinces are rapidly reshaping Canada's conventional and luxury real estate market.Dramatic interprovincial migration trends are now...

at 05:55
Traditions Bancorp, Inc. , the parent company of Traditions Bank, reported net income of $1.8 million for the second quarter ended June 30, 2024, compared to $1.4 million in the linked quarter and $1.3 million for the second quarter of 2023. The...

at 05:45
OTC Global Holdings , the leading independent interdealer broker in over-the-counter commodities, doubled-down on its proprietary technology and market data platform, EOXLive and EOX Market Data during a commodity brokerage round table attended by...

at 05:35
Allegion plc , a leading global security products and solutions provider, today reported financial results for its second quarter (ended June 30, 2024). "Strong execution by the entire Allegion team drove record Q2 revenue and adjusted EPS," said...

News published on and distributed by: